PE20031037A1 - Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades - Google Patents
Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedadesInfo
- Publication number
- PE20031037A1 PE20031037A1 PE2003000150A PE2003000150A PE20031037A1 PE 20031037 A1 PE20031037 A1 PE 20031037A1 PE 2003000150 A PE2003000150 A PE 2003000150A PE 2003000150 A PE2003000150 A PE 2003000150A PE 20031037 A1 PE20031037 A1 PE 20031037A1
- Authority
- PE
- Peru
- Prior art keywords
- nicotinamide
- combination
- fluoro
- tiotrope
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
SE REFIERE A UNA COMBINACION DE TIOTROPIO O UN DERIVADO DEL MISMO CON UN COMPUESTO DE FORMULA I DONDE R1 Y R2 SON H, HALO, CIANO, ALQUILO C1-C4, ALCOXI C1-C4; X ES -O-, -S-, NH; R3 ES UN MIEMBRO SELECCIONADO DE FENILO, NAFTILO, HETEROARILO, CICLOALQUILO C3-C8 CON HALO, CIANO, TRIFLUOROMETILO, TRIFLUOROETILO, TRIFLUOROMETOXI, ENTRE OTROS; R4 ES FENILO, NAFTILO, HETEROARILO, CICLOALQUILO C3-C8, ENTRE OTROS; Y ES EL GRUPO (1.6), (1.7) ENTRE OTROS; Z ES EL GRUPO (1.10), (1.11) ENTRE OTROS; * INDICA EL PUNTO DE UNION. SON COMPUESTOS PREFERIDOS ANTI-2-(BENZO[1,3]DIOXOL-5-ILOXI)-N-[4-(2-HIDROXI-BENZOIL-AMINA)-CICLOHEXIL]-NICOTINAMIDA, ANTI-N-[4-(2-FLUORO-6-HIDROXI-BENZOILAMINO)-CICLOHEXIL]-2-(4-FLUORO-FENOXI)-NICOTINAMIDA, ANTI-5-FLUORO-2-(3,4-DIFLUORO-FENOXI)-N-[4-(2-FLUORO-6-HIDROXI-BENZOAMINO)-CICLOHEXIL]NICOTINAMIDA, ENTRE OTROS. LA COMBINACION ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, ALERGICAS, RESPIRATORIAS
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0203196A GB0203196D0 (en) | 2002-02-11 | 2002-02-11 | Nicotinamide derivatives useful as pde4 inhibitors |
GB0220984A GB0220984D0 (en) | 2002-09-10 | 2002-09-10 | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases |
GB0224454A GB0224454D0 (en) | 2002-10-21 | 2002-10-21 | Nicotinamide derivatives and a tiotropium salt in combination for the treatmentof diseases |
GB0227140A GB0227140D0 (en) | 2002-11-20 | 2002-11-20 | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20031037A1 true PE20031037A1 (es) | 2003-12-24 |
Family
ID=27739228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000150A PE20031037A1 (es) | 2002-02-11 | 2003-02-11 | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades |
Country Status (10)
Country | Link |
---|---|
US (1) | US20030220361A1 (es) |
AR (1) | AR038835A1 (es) |
AU (1) | AU2003201745A1 (es) |
DO (1) | DOP2003000585A (es) |
HN (1) | HN2003000063A (es) |
PA (1) | PA8566301A1 (es) |
PE (1) | PE20031037A1 (es) |
TW (1) | TW200305416A (es) |
UY (1) | UY27656A1 (es) |
WO (1) | WO2003068233A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS70104A (en) | 2002-02-11 | 2007-02-05 | Pfizer Limited, | Nicotinamide derivatives useful as pde4 inhibitors |
WO2004071527A1 (en) * | 2003-02-11 | 2004-08-26 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
SG137859A1 (en) | 2003-11-03 | 2007-12-28 | Boehringer Ingelheim Int | Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same |
US8597947B2 (en) | 2004-12-29 | 2013-12-03 | Hadasit Medical Research Services & Development Limited | Undifferentiated stem cell culture systems |
EP2410043A3 (en) | 2004-12-29 | 2013-01-23 | Hadasit Medical Research Services And Development Ltd. | Stem cells culture systems |
EP2554661B2 (en) | 2007-04-18 | 2018-02-21 | Hadasit Medical Research Services & Development Limited | Stem cell-derived retinal pigment epithelial cells |
WO2009035928A1 (en) * | 2007-09-11 | 2009-03-19 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
EP2297106B1 (en) * | 2008-05-27 | 2014-07-16 | AstraZeneca AB | Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states |
IL305070A (en) | 2014-12-30 | 2023-10-01 | Cell Cure Neurosciences Ltd | RPE cell populations and methods for their production |
US20180011092A1 (en) | 2014-12-30 | 2018-01-11 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
JP7055095B2 (ja) | 2015-07-29 | 2022-04-15 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | 網膜色素上皮細胞の大規模生産 |
PL3331994T3 (pl) | 2015-08-05 | 2023-01-30 | Cell Cure Neurosciences Ltd. | Wytwarzanie komórek nabłonka barwnikowego siatkówki |
EP3331995A1 (en) | 2015-08-05 | 2018-06-13 | Cell Cure Neurosciences Ltd. | Preparation of photoreceptors for the treatment of retinal diseases |
CA3002919A1 (en) | 2015-10-26 | 2017-05-04 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
WO2018170494A1 (en) | 2017-03-16 | 2018-09-20 | Bio Time, Inc. | Methods for measuring therapeutic effects of retinal disease therapies |
WO2019130061A2 (en) | 2017-12-29 | 2019-07-04 | Cell Cure Neurosciences Ltd. | Retinal pigment epithelium cell compositions |
CA3112135A1 (en) | 2018-09-20 | 2020-03-26 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral sclerosis |
EP3754014A1 (en) | 2019-06-21 | 2020-12-23 | Centre d'Etude des Cellules Souches (CECS) | Automated method for preparing retinal pigment epithelium cells |
WO2022261320A1 (en) | 2021-06-09 | 2022-12-15 | Lineage Cell Therapeutics, Inc. | Methods and compositions for treating retinal diseases and conditions |
CA3225834A1 (en) | 2021-07-28 | 2023-02-02 | Lineage Cell Therapeutics, Inc. | Expansion of retinal pigment epithelium cells |
WO2023211857A1 (en) | 2022-04-25 | 2023-11-02 | Lineage Cell Therapeutics, Inc. | Methods and compositions for treating vision loss |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
PL336148A1 (en) * | 1997-04-04 | 2000-06-05 | Pfizer Prod Inc | Nicotinamide derivatives |
-
2003
- 2003-02-03 AU AU2003201745A patent/AU2003201745A1/en not_active Abandoned
- 2003-02-03 WO PCT/IB2003/000378 patent/WO2003068233A1/en not_active Application Discontinuation
- 2003-02-06 TW TW92102409A patent/TW200305416A/zh unknown
- 2003-02-06 US US10/360,100 patent/US20030220361A1/en active Pending
- 2003-02-10 HN HN2003000063A patent/HN2003000063A/es unknown
- 2003-02-10 AR ARP030100405 patent/AR038835A1/es not_active Application Discontinuation
- 2003-02-11 PA PA8566301A patent/PA8566301A1/es unknown
- 2003-02-11 UY UY27656A patent/UY27656A1/es not_active Application Discontinuation
- 2003-02-11 PE PE2003000150A patent/PE20031037A1/es not_active Application Discontinuation
- 2003-02-11 DO DO2003000585A patent/DOP2003000585A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003201745A1 (en) | 2003-09-04 |
TW200305416A (en) | 2003-11-01 |
US20030220361A1 (en) | 2003-11-27 |
WO2003068233A1 (en) | 2003-08-21 |
UY27656A1 (es) | 2003-09-30 |
PA8566301A1 (es) | 2003-11-12 |
DOP2003000585A (es) | 2003-09-30 |
AR038835A1 (es) | 2005-01-26 |
HN2003000063A (es) | 2004-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20031037A1 (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades | |
DE60123800D1 (de) | Salze von benzimidazol-derivaten und deren verwendung | |
CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
PE20090837A1 (es) | Nuevos compuestos quimicos | |
PE20030921A1 (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades | |
GEP20074055B (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
PE20060693A1 (es) | Nuevos derivados de trifluorometansulfonanilida oxamida eter | |
SV2003001054A (es) | Derivados de pirroles nuevos como agentes farmaceuticos ref. x-15017 | |
PE20020220A1 (es) | Compuestos de nitrilo de dipeptido como inhibidores de catepsina k | |
EA200200662A1 (ru) | Никотинамидные бензоконденсированные гетероциклические производные, полезные в качестве селективных ингибиторов pde4-изозимов | |
HUP0500610A2 (hu) | Indazol-, benzotiazol- és benzoizotiazol-származékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása | |
ES2063094T3 (es) | Derivados de oximeter, procedimiento para su obtencion y fungicidas que les contienen. | |
DE69930926D1 (de) | Benzolsulfonamid-derivate und ihre anwendung als arzneimittel | |
MEP51408A (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
BR0015193A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas | |
DE602005022764D1 (de) | Piperidin- und azetidinderivate als glyt1-inhibitoren | |
EA199800912A1 (ru) | Дигидратная соль мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2(1н)-индол-2-она, фармацевтическая композиция и способ лечения психотического расстройства | |
KR970703333A (ko) | 5-HT_1A 길항제로서의 피페라진 유도체(Piperazine derivatives as 5-HT_1A antagonists) | |
PE20001088A1 (es) | Compuestos derivados de tetrahidrobenzazepina | |
HRP20050628A2 (en) | Substituted benzoyl derivatives uses as herbicides | |
DE69526862D1 (de) | Azol-derivate | |
BR0213970A (pt) | Amidas de ácido antranìlico e uso farmacêutico dessas amidas | |
AR056455A1 (es) | Mezclas pesticidas | |
PE20050329A1 (es) | Derivados de nicotinamida como inhibidores de fosfodiesterasa pde4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |